Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Up 6.2% in October

Hims & Hers Health, Inc. (NYSE:HIMS) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 33,840,000 shares, a growth of 6.2% from the October 15th total of 31,870,000 shares. Based on an average daily volume of 10,980,000 shares, the short-interest ratio is currently 3.1 days. Approximately 19.1% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Piper Sandler reissued a “neutral” rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their target price for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Finally, TD Cowen raised their target price on Hims & Hers Health from $25.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $20.71.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. This trade represents a 84.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christiane Pendarvis sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the transaction, the director now owns 23,917 shares in the company, valued at approximately $362,342.55. This trade represents a 22.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 996,961 shares of company stock worth $20,256,416 over the last three months. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC grew its holdings in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the period. Quest Partners LLC lifted its position in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares in the last quarter. CWM LLC lifted its position in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares in the last quarter. Van ECK Associates Corp acquired a new position in Hims & Hers Health during the 2nd quarter worth approximately $111,000. Finally, Quarry LP raised its position in shares of Hims & Hers Health by 91.0% in the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after purchasing an additional 2,913 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 8.9 %

Shares of NYSE:HIMS traded up $1.86 during midday trading on Tuesday, hitting $22.85. 14,881,520 shares of the stock were exchanged, compared to its average volume of 9,347,936. The stock has a market cap of $4.99 billion, a P/E ratio of 50.46 and a beta of 1.06. Hims & Hers Health has a twelve month low of $7.50 and a twelve month high of $30.44. The company has a 50 day moving average price of $19.90 and a 200-day moving average price of $18.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.04) EPS. On average, equities research analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.